Trial · NCT06409026
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
NCT06409026, Phase 4, Completed, Mayo Clinic
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension. Trials, record NCT06409026. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06409026
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
- NCT number
- NCT06409026
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 30 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept
- First posted
- 2024-05-10
- Last updated
- 2026-04-16
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pulmonary arterial mean pressure/Cardiac Output (PA/CO) at peak exercise | Baseline, Week 24 | Peak exercise pulmonary arterial mean pressure/ Cardiac output (mm Hg/L/min) |
| Secondary | Oxygen Consumption (VO2) | Baseline, 24 weeks | VO2 will be measured in mL/kg/min. It will be directly measured using expired gas analysis. |
| Secondary | Single leg blood flow at peak exercise | Baseline, 24 weeks | Single leg blood flow will be obtained from venous access. Single leg blood flow will be measured in ml/min |
| Secondary | Pulmonary vascular resistance at rest | Baseline, 24 weeks | Pulmonary vascular resistance will be measured in Wood units (mmHg/L/min) |
| Secondary | Pulmonary vascular resistance at peak exercise | Baseline, 24 weeks | Pulmonary vascular resistance will be measured in Wood units (mmHg/L/min) |
| Secondary | Pulmonary arterial (PA) compliance at rest | Baseline, 24 weeks | PA compliance measures pulmonary arterial distensibility and will be recorded at Baseline and 24 Weeks. PA compliance will be measured in ml/mm Hg. |
| Secondary | Pulmonary arterial (PA) compliance at peak exercise | Baseline, 24 weeks | PA compliance measures pulmonary arterial distensibility and will be recorded at Baseline and 24 Weeks. PA compliance will be measured in ml/mm Hg. |
| Secondary | Pulmonary arterial elastance at rest | Baseline, 24 weeks | PA elastance measures pulmonary artery stiffness and will be recorded at baseline and 24 weeks as PA systolic pressure/stroke volume (units mm Hg/ml) |
| Secondary | Pulmonary arterial elastance at peak exercise | Baseline, 24 weeks | PA elastance measures pulmonary artery stiffness and will be recorded at baseline and 24 weeks as PA systolic pressure/stroke volume (units mm Hg/ml) |
| Secondary | Left ventricular (LV) transmural pressure at rest | Baseline, 24 weeks | LV transmural pressure will measured by catheterization at Baseline and 24 Weeks as the difference between pulmonary capillary wedge pressure and right atrial pressure |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06409026
GET https://conductscience.org/api/trials/v1/NCT06409026/registered